Millions of new cases of cancer are diagnosed worldwide each year, making it a serious public health concern. Developments in customized therapy and early detection have significantly enhanced treatment for and results from cancer. Therefore, it is important to investigate new molecular biomarkers. In this study, we created an efficient transient receptor potential melastatin (TRPM) family members-related TRPM-Score for 17 solid tumors. CCNE1, produced from TRPM-Score, was found to be an exceptional biomarker through several sophisticated machine learning and deep learning computational techniques. TRPM-Score and CCNE1 immunotherapeutic prediction, immunological characteristics, and predictive value were thoroughly assessed. In most cancer types, CCNE1 was a substantially dangerous marker. Additional in vitro tests validated CCNE1’s immunomodulatory properties, demonstrating that silencing impeded macrophage movement and decreased PD-L1 expression. Additionally, CCNE1 may accurately predict responses to cancer immunotherapy. These findings indicate that the TRPM family—particularly CCNE1, which is associated with TRPM—is a significant player in the pan-cancer domain and can be utilized as a therapeutic target and prognostic biomarkers, especially in immuno-oncology. The thorough characterization of the TRPM family and the discovery of CCNE1 as a crucial downstream effector mark important developments in our comprehension of pan-cancer biology.

中文翻译：

---

揭示瞬时受体电位美拉他汀家族相关 CCNE1 在泛癌中的预测和免疫调节潜力


全球每年诊断出数百万新癌症病例，使其成为一个严重的公共卫生问题。定制疗法和早期检测的发展显着增强了癌症的治疗和结果。因此，研究新的分子生物标志物很重要。在这项研究中，我们为 17 例实体瘤创建了一个高效的瞬时受体电位美拉他汀 （TRPM） 家族成员相关 TRPM-Score。CCNE1 由 TRPM-Score 产生，通过几种复杂的机器学习和深度学习计算技术被发现是一种特殊的生物标志物。全面评估 TRPM-Score 和 CCNE1 免疫治疗预测、免疫学特征和预测价值。在大多数癌症类型中，CCNE1 是一种非常危险的标志物。额外的体外测试验证了 CCNE1 的免疫调节特性，表明沉默会阻碍巨噬细胞运动并降低 PD-L1 表达。此外，CCNE1 可以准确预测对癌症免疫治疗的反应。这些发现表明，TRPM 家族——尤其是与 TRPM 相关的 CCNE1——是泛癌领域的重要参与者，可用作治疗靶点和预后生物标志物，尤其是在免疫肿瘤学中。TRPM 家族的彻底表征和 CCNE1 作为关键下游效应子的发现标志着我们对泛癌生物学理解的重要进展。